Avatar

CAR T and NK Cell Therapy in Myeloma

By Parameswaran Hari 5 Videos
August 6, 2018
1 Comment
Login to view comments. Click here to Login

Related Content

AUTOPLAY
The O'Neal Comprehensive Cancer Center at UAB

UAB Hematology Review 2021

Fri, Mar 5, 2021
22:47
UChicago CAR T-Cell Symposium 2019

Patient Selection for CAR T-Cell Therapy: Therapeutic Benefits, Discussion…

Feat. M. Leukam
23:48
UChicago CAR T-Cell Symposium 2019

2019 Update on CAR-T in Multiple Myeloma - Can We Improve Upon These Res...

Feat. J. Jasielec
06:21
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Relapsed/Refractory: CAR T Cells - A New Frontier in ...

Feat. F. Anwer
27:06
UChicago CAR T-Cell Symposium 2019

Why Does CAR T-Cell Therapy Fail? An Update on Mechanisms of Resistance/Re…

Feat. J. Kline
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

07:57
Penn Medicine 2020 Updates in Oncology

ASCO Update on Myeloma: How Promising Are BCMA CAR-T & BCMA x CD3 Bispec...

Feat. D. Vogl
15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Mana…

Feat. S. Lonial
15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Response to...

Feat. A. Rosko
07:23
Indy Hematology Review

Novel Immune Therapies in Myeloma: BCMA Immunotoxin, Bites, and CAR T cells

Feat. K. Anderson
27:01
SOHO Italy 1st School of Multiple Myeloma

Europe vs. USA Experience in MM: Access to New Drugs (Off-Label vs Approve…

Feat. K. Anderson
12:32
Indy Hematology Review

What's New in Immunotherapy and Genomics in Multiple Myeloma?

Feat. K. Anderson
15:10
Krina Patel

Developing CAR T-cells in Multiple Myeloma

13:30
Helen Heslop

CAR T-cell Therapy for Hematologic Malignancies Other Than CD19

14:43
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

What Will The Future Hold for Myeloma Treatment CARTs vs BiTES?

Feat. R. Orlowski
09:46
2018 Pan Pacific Lymphoma Conference

CAR T-cell Toxicities and Team Management

Feat. S. Blumel
10:38
Krina Patel

How Do We Make Responses Durable in Multiple Myeloma?

17:44
UChicago CAR T-Cell Symposium 2019

Current Grading and Management Strategies of CAR-T Toxicities: Cytokine Re…

Feat. S. Kosuri
06:41
UChicago CAR T-Cell Symposium 2019

Mechanisms of Acquired CAR-T Cell Resistance: Is There a 'Best' in Produ...

Feat. J. Labelle
22:21
UChicago CAR T-Cell Symposium 2019

Immune Regulation and Chimeric Antigen Receptor (CAR) T-Cell Therapy: Me...

Feat. J. Labelle
26:41
Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient

BCMA - Based Immunotherapy for Myeloma: Belantamab Mafodotin, CAR-T Cells …

Feat. A. Cohen